HUE049337T2 - Eljárás indolamin-2,3-dioxigenáz inhibitor elõállítására - Google Patents

Eljárás indolamin-2,3-dioxigenáz inhibitor elõállítására

Info

Publication number
HUE049337T2
HUE049337T2 HUE14812015A HUE14812015A HUE049337T2 HU E049337 T2 HUE049337 T2 HU E049337T2 HU E14812015 A HUE14812015 A HU E14812015A HU E14812015 A HUE14812015 A HU E14812015A HU E049337 T2 HUE049337 T2 HU E049337T2
Authority
HU
Hungary
Prior art keywords
indoleamine
synthesis
dioxygenase inhibitor
dioxygenase
inhibitor
Prior art date
Application number
HUE14812015A
Other languages
English (en)
Inventor
Ming Tao
William Frietze
David J Meloni
Lingkai Weng
Jiacheng Zhou
Yongchun Pan
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of HUE049337T2 publication Critical patent/HUE049337T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
HUE14812015A 2013-11-08 2014-11-07 Eljárás indolamin-2,3-dioxigenáz inhibitor elõállítására HUE049337T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361901689P 2013-11-08 2013-11-08

Publications (1)

Publication Number Publication Date
HUE049337T2 true HUE049337T2 (hu) 2020-09-28

Family

ID=52023608

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14812015A HUE049337T2 (hu) 2013-11-08 2014-11-07 Eljárás indolamin-2,3-dioxigenáz inhibitor elõállítására

Country Status (31)

Country Link
US (3) US9321755B2 (hu)
EP (2) EP3744715A1 (hu)
JP (4) JP6461953B2 (hu)
KR (2) KR102617531B1 (hu)
CN (2) CN105899498B (hu)
AR (1) AR098343A1 (hu)
AU (2) AU2014346647B2 (hu)
BR (2) BR112016009786B1 (hu)
CA (1) CA2929552C (hu)
CL (1) CL2016001082A1 (hu)
CR (2) CR20160252A (hu)
CY (1) CY1123164T1 (hu)
DK (1) DK3066085T3 (hu)
EA (2) EA201991770A1 (hu)
ES (1) ES2799582T3 (hu)
HR (1) HRP20201089T1 (hu)
HU (1) HUE049337T2 (hu)
IL (2) IL245314B (hu)
LT (1) LT3066085T (hu)
ME (1) ME03792B (hu)
MX (2) MX366874B (hu)
MY (1) MY174254A (hu)
PE (2) PE20160863A1 (hu)
PH (2) PH12016500818B1 (hu)
PL (1) PL3066085T3 (hu)
PT (1) PT3066085T (hu)
RS (1) RS60598B1 (hu)
SG (2) SG10201803874PA (hu)
SI (1) SI3066085T1 (hu)
TW (4) TWI696618B (hu)
WO (1) WO2015070007A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013977A (es) 2005-05-10 2008-02-05 Incyte Corp Moduladores de 2,3-dioxigenasa indolamina y metodos de uso de los mismos.
KR101927291B1 (ko) * 2008-07-08 2018-12-10 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
HUE049337T2 (hu) 2013-11-08 2020-09-28 Incyte Holdings Corp Eljárás indolamin-2,3-dioxigenáz inhibitor elõállítására
BR112016017700A2 (pt) * 2014-02-04 2017-10-10 Incyte Corp método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
AU2016293667A1 (en) * 2015-07-14 2018-01-04 Kyowa Kirin Co., Ltd. A therapeutic agent for a tumor comprising an IDO inhibitor administered in combination with an antibody
CA3004083A1 (en) 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
US10538497B2 (en) 2015-12-15 2020-01-21 Merck Sharp & Dohme Corp. Compounds as indoleamine 2,3-dioxygenase inhibitors
US9624185B1 (en) * 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
US11046682B2 (en) 2016-08-23 2021-06-29 Beijing Innocare Pharma Tech Co., Ltd. Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof
WO2018054365A1 (en) 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
SI3559009T1 (sl) 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
CN109206380A (zh) * 2017-07-03 2019-01-15 上海时莱生物技术有限公司 吲哚胺2，3-双加氧酶抑制剂化合物及其制备方法和用途
CN110066253B (zh) * 2018-01-24 2023-06-23 江苏柯菲平医药股份有限公司 1,2,5-噁二唑类衍生物，其制备方法及其在医药中的应用
CN108101899B (zh) * 2018-02-11 2021-01-26 中国药科大学 IDO1抑制剂Epacadostat中间体的制备方法
CN109180603A (zh) * 2018-10-10 2019-01-11 中国药科大学 Epacadostat关键中间体的制备方法
CN114502196A (zh) 2019-08-01 2022-05-13 因赛特公司 Ido抑制剂的给药方案
US20220409581A1 (en) * 2019-11-14 2022-12-29 Nova Southeastern University Methods and compositions for treatment of solid tumors using f16 isoindole small molecules
CN112341403B (zh) * 2020-11-10 2022-06-28 南京工业大学 一种利用微流场反应技术制备3-氨基-4-偕胺肟基呋咱的方法
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236855A (en) 1964-01-17 1966-02-22 Merck & Co Inc Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en) 1964-02-19 1967-11-21 Sterling Drug Inc 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
US3553228A (en) 1967-09-26 1971-01-05 Colgate Palmolive Co 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (de) 1970-08-17 1972-02-24 Fahlberg List Veb Neue herbizide Mittel
US3948928A (en) 1972-03-17 1976-04-06 Dainippon Pharmaceutical Co., Ltd. 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (hu) 1973-09-05 1981-05-16
FR2323683A1 (fr) 1975-09-11 1977-04-08 Philagro Sa Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent
CA1080234A (en) 1975-09-11 1980-06-24 Daniel Farge Derivatives of amidoximes
US4323681A (en) 1980-09-29 1982-04-06 American Home Products Corporation 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
JPS58208275A (ja) 1982-05-20 1983-12-03 Lion Corp ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
EP0132680B1 (de) 1983-07-22 1987-01-28 Bayer Ag Substituierte Furazane
US4507485A (en) 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (ja) 1984-03-13 1985-10-02 Toyo Jozo Co Ltd シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法
JPS6259283A (ja) 1985-09-10 1987-03-14 Kaken Pharmaceut Co Ltd セフアロスポリン化合物
JP2696342B2 (ja) 1988-06-27 1998-01-14 日本曹達株式会社 アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
DE68901424D1 (de) 1988-07-05 1992-06-11 Akzo Nv Verbindungen mit bronchodilatatorischer aktivitaet.
JPH04297449A (ja) 1991-03-27 1992-10-21 Hokko Chem Ind Co Ltd Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤
JPH05186458A (ja) 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
JP2709677B2 (ja) 1992-06-19 1998-02-04 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
FR2720396B1 (fr) 1994-05-27 1996-06-28 Adir Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5731315A (en) 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
EP0858451A1 (en) 1995-10-17 1998-08-19 Astra Pharmaceuticals Limited Pharmaceutically active quinazoline compounds
AU1730497A (en) 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en) 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
JPH11171702A (ja) 1997-09-24 1999-06-29 Takeda Chem Ind Ltd 害虫防除方法
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
BR9813536A (pt) 1997-12-10 2000-10-10 Dainippon Ink & Chemicals "derivados oxima e produtos quìmicos agrìcolas incluindo os mesmos"
WO1999062903A1 (en) 1998-06-02 1999-12-09 Takeda Chemical Industries, Ltd. Oxadiazoline derivatives and their use as insecticides
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CN100354271C (zh) 1999-03-03 2007-12-12 三进制药株式会社 哌嗪衍生物及其制备方法
TR200102912T2 (tr) 1999-04-09 2002-03-21 Basf Ag. Trombin ihtibit”rlerinin ”n ila‡larì.
ES2244438T3 (es) 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
JP2001158785A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 農薬組成物
JP2001158786A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 哺乳動物の外部寄生虫防除剤
WO2001051456A2 (en) 2000-01-13 2001-07-19 Tularik Inc. Antibacterial agents
JP2001233861A (ja) 2000-02-22 2001-08-28 Ube Ind Ltd ピラゾールオキシム化合物、その製法及び用途
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
IL159219A0 (en) 2001-06-18 2004-06-01 Applied Research Systems Pyrrolidine oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
AU2003218989A1 (en) 2002-02-19 2003-09-09 Pharmacia Italia S.P.A. Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
CA2483451C (en) 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
TW200406395A (en) 2002-05-28 2004-05-01 Dimensional Pharm Inc Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7015321B2 (en) * 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
CA2520586C (en) 2003-03-27 2011-06-14 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
CA2536253A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
KR101011848B1 (ko) 2004-09-08 2011-02-01 미쓰비시 타나베 파마 코퍼레이션 모르폴린 화합물
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
MX2007013977A (es) 2005-05-10 2008-02-05 Incyte Corp Moduladores de 2,3-dioxigenasa indolamina y metodos de uso de los mismos.
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
JP2008544818A (ja) 2005-06-30 2008-12-11 アントフロゲネシス コーポレーション 胎盤由来コラーゲンバイオ線維を用いた鼓膜の修復
DE102005060466A1 (de) 2005-12-17 2007-06-28 Bayer Cropscience Ag Carboxamide
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (ja) 2006-05-12 2009-07-15 株式会社サクラクレパス 墨汁
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080119491A1 (en) 2006-09-19 2008-05-22 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008058178A1 (en) * 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2009128521A1 (ja) * 2008-04-15 2009-10-22 帝人ファーマ株式会社 システインプロテアーゼ阻害剤
KR101927291B1 (ko) * 2008-07-08 2018-12-10 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
HUE049337T2 (hu) 2013-11-08 2020-09-28 Incyte Holdings Corp Eljárás indolamin-2,3-dioxigenáz inhibitor elõállítására

Also Published As

Publication number Publication date
EP3066085B1 (en) 2020-05-13
MX2019008378A (es) 2019-09-09
JP2017500284A (ja) 2017-01-05
AR098343A1 (es) 2016-05-26
PH12016500818A1 (en) 2016-06-20
EA033667B1 (ru) 2019-11-14
BR112016009786B1 (pt) 2021-01-05
KR20210126157A (ko) 2021-10-19
MX2016005954A (es) 2016-12-07
JP2020019805A (ja) 2020-02-06
TW202309014A (zh) 2023-03-01
JP2019038811A (ja) 2019-03-14
EP3744715A1 (en) 2020-12-02
ME03792B (me) 2021-04-20
US9873688B2 (en) 2018-01-23
IL245314B (en) 2019-07-31
PT3066085T (pt) 2020-07-16
CL2016001082A1 (es) 2016-12-09
EP3066085A1 (en) 2016-09-14
US9321755B2 (en) 2016-04-26
SG10201803874PA (en) 2018-07-30
PE20160863A1 (es) 2016-09-03
IL245314A0 (en) 2016-06-30
RS60598B1 (sr) 2020-08-31
AU2014346647B2 (en) 2018-10-25
CN109810104B (zh) 2022-05-03
CN105899498A (zh) 2016-08-24
IL267773B (en) 2020-04-30
TWI696618B (zh) 2020-06-21
TW202100523A (zh) 2021-01-01
PH12019500770A1 (en) 2020-09-21
TWI651311B (zh) 2019-02-21
KR20160094971A (ko) 2016-08-10
EA201690959A1 (ru) 2016-08-31
CA2929552A1 (en) 2015-05-14
SI3066085T1 (sl) 2020-08-31
ES2799582T3 (es) 2020-12-18
IL267773A (en) 2019-09-26
LT3066085T (lt) 2020-06-25
US20150133674A1 (en) 2015-05-14
CY1123164T1 (el) 2021-10-29
CR20190351A (es) 2019-10-07
PE20220430A1 (es) 2022-03-29
CN109810104A (zh) 2019-05-28
US20160221996A1 (en) 2016-08-04
US20180244663A1 (en) 2018-08-30
DK3066085T3 (da) 2020-06-02
EA201991770A1 (ru) 2019-12-30
JP6461953B2 (ja) 2019-01-30
US10280157B2 (en) 2019-05-07
JP6633163B2 (ja) 2020-01-22
TW201920158A (zh) 2019-06-01
CR20160252A (es) 2016-09-19
PH12016500818B1 (en) 2016-06-20
KR102617531B1 (ko) 2023-12-27
CN105899498B (zh) 2019-01-25
SG11201603433UA (en) 2016-05-30
AU2019200404A1 (en) 2019-02-07
KR102370067B1 (ko) 2022-03-04
JP6883079B2 (ja) 2021-06-09
JP6913725B2 (ja) 2021-08-04
PL3066085T3 (pl) 2020-11-02
WO2015070007A1 (en) 2015-05-14
MY174254A (en) 2020-04-01
MX366874B (es) 2019-07-29
TWI775079B (zh) 2022-08-21
BR122020009912B1 (pt) 2022-11-01
AU2014346647A1 (en) 2016-05-26
CA2929552C (en) 2022-05-17
AU2019200404B2 (en) 2021-03-04
TW201605817A (zh) 2016-02-16
NZ719822A (en) 2021-11-26
HRP20201089T1 (hr) 2020-10-30
JP2020019806A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
IL267773B (en) A process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
HK1247922A1 (zh) 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
IL241322A0 (en) Indoleamine 2, 3-dioxygenase (ido) inhibitors
EP3389783A4 (en) NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
HK1215256A1 (zh) 用作吲哚胺 -二氧化酶的抑制劑的化合物
HK1218414A1 (zh) 用於合成手性犬尿氨酸化合物的方法
HK1219737A1 (zh) 用於治療癌症的新化合物
EP2948437A4 (en) NEW APPROACH FOR THE SYNTHESIS OF CATÉCHINES
ZA201603457B (en) Novel method for the synthesis of agomelatine
IL243937A0 (en) A process for the purification of diaminophenothiazinium compounds
PT2799426T (pt) Novo processo para a síntese de aminaftona
ME02213B (me) Postupak sinteze derivata 7,8-dimetoksi-1,3-dihidr0-2h-3-benzazepin-2-0na i njihova upotreba za pripravu ivabradina
TH1601002537A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง
IL244411B (en) Procedure for the synthesis of derivatives of n-benzyl-n-cyclopropyl-1h-pyrazole-4-carboxamide
GB201408238D0 (en) Synthesis of substituted 1,2,3-Triazoles
AP2015008905A0 (en) Novel compounds for the treatment of cancer